Optima Health to acquire Care first, a leading provider of mental health services, for a net consideration of £15,000, adding c.£3.7 million revenue to the GroupAcquisition provides Optima with increased scale in its Mental Health division and will complement its existing Employee Assistance Programme (“EAP”) service offering, bringing over 1,000 new customers, and c.40 employeesAligns with strategy of consolidating margin accretive businesses in areas with significant existing expertise, creating additiona ...

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain. Optima Health plc(“Optima”, the “Company”, and, together with its subsidiaries, the “Group”) Opt ...

Core Insights - Optiva Inc. reported its fourth quarter financial results for the period ending December 31, 2024, highlighting a focus on cloud-native billing and revenue management solutions for the telecom industry [2][8]. Business Highlights - In Q4 2024, Optiva gained one new customer, bringing the total to five new customers for the year. Additionally, five existing customers opted for upgrades and renewals, including significant enhancements to the Optiva Charging Engine [3][9]. - The company announced the integration of agentic AI into its BSS platform and charging engine, utilizing Google's Gemini models, which enhances operational efficiency and customer experience [4][12]. - Optiva's participation in the Mobile World Congress 2025 saw a 20% increase in meeting traffic, indicating strong market interest in its AI and monetization capabilities [5]. Financial Performance - Q4 2024 revenue was $12.0 million, consistent with Q4 2023. For the full year, total revenue was $47.1 million, slightly down from $47.5 million in 2023 [11][14]. - The company reported a gross margin of 59% for Q4 2024, down from 63% in the same period last year, primarily due to lower-margin customizations [14]. - Adjusted EBITDA loss remained at $1.8 million for Q4 2024, unchanged from the previous year, while the net loss for the quarter was $4.7 million compared to $4.0 million in Q4 2023 [19][11]. Strategic Developments - Optiva's partnerships with major telecom operators, such as Omantel and BH Telecom, have led to successful upgrades to cloud-native, 5G-enabled platforms, enhancing their service offerings [9][10]. - The company is actively exploring refinancing options for its PIK Toggle Notes maturing in July 2025, indicating ongoing strategic financial management [7][22]. Market Position - Optiva's MVNO Hubs are designed to attract larger MVNOs and MVNEs, emphasizing the importance of a fully digital BSS for competitive operational costs [6]. - The company aims to leverage its cloud-native solutions to capitalize on emerging market opportunities in digital, 5G, and IoT sectors [20].

Core Viewpoint - Opthea Limited's Phase 3 clinical trial COAST for treating wet age-related macular degeneration (wet AMD) failed to meet its primary endpoint, raising concerns about the company's future and obligations under its Development Funding Agreement [1][2][5]. Group 1: Trial Results - The COAST trial evaluated the efficacy and safety of sozinibercept in combination with aflibercept, but did not achieve the primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 [2]. - In patients with minimally classic and occult lesions, the mean change in BCVA was 13.2 letters for both dosing regimens (every four weeks and every eight weeks) compared to 13.8 letters for aflibercept monotherapy [3]. - The overall population showed a mean change in BCVA of 13.5 letters for the four-week regimen and 12.8 letters for the eight-week regimen, versus 13.7 letters for aflibercept monotherapy [3]. Group 2: Financial and Operational Impact - Following the negative trial results, Opthea is assessing its rights and obligations under the Development Funding Agreement, which may require significant payments to investors, potentially impacting the company's solvency [5][9]. - The potential repayment amounts under the DFA could range from US$0 to US$680 million, depending on various termination triggers [5]. - Opthea's management is in discussions with DFA Investors to explore options for the clinical trial program and to identify a favorable outcome for the company and its shareholders [6]. Group 3: Current Financial Status - As of February 28, 2025, Opthea reported an unaudited cash and cash equivalents balance of US$113.8 million [8]. - The company has requested a suspension of trading in its securities on both ASX and Nasdaq until further clarity on its situation can be provided [10].

Core Insights - Opthea Limited announced the publication of Phase 2b data for sozinibercept in treating wet age-related macular degeneration (wet AMD) in the journal Ophthalmic Surgery, Lasers and Imaging Retina [1][2] Company Overview - Opthea is a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases, particularly wet AMD and diabetic macular edema [8][9] - The lead product candidate, sozinibercept, is a first-in-class VEGF-C/D 'trap' inhibitor being evaluated in combination with standard anti-VEGF-A therapies [9] Clinical Trial Results - The Phase 2b study showed that sozinibercept combination therapy led to superior visual gains compared to ranibizumab monotherapy at 24 weeks [2][6] - In patients with occult and minimally classic lesions (73% of the total population), sozinibercept demonstrated a statistically significant additional 5.7 letter mean gain in best corrected visual acuity (BCVA) compared to ranibizumab alone [3][6] - The combination therapy also resulted in a greater proportion of patients gaining ≥15 letters and improved anatomical outcomes, including reduced choroidal neovascularization (CNV) area [3][6] Future Clinical Development - Opthea's pivotal Phase 3 program includes two trials, COAST and ShORe, designed to assess the safety and efficacy of sozinibercept combination therapy versus standard anti-VEGF-A treatments [5] - The company anticipates topline data readouts for COAST in early Q2 CY 2025 and for ShORe in mid-CY 2025 [4] Market Context - Wet AMD is a leading cause of vision loss in the elderly, affecting approximately 3.5 million people in the US and Europe [4] - There is a significant unmet medical need in wet AMD, as many patients do not achieve optimal vision outcomes with existing anti-VEGF-A therapies [4]

Core Viewpoint - Opthea Limited is progressing towards delivering innovative therapies for wet age-related macular degeneration (wet AMD), with significant advancements expected in its clinical trials and financial management [2][3]. Financial Results and Highlights - For the six months ended December 31, 2024, Opthea reported a net loss of US$131.9 million, an increase from US$101.7 million in the same period of 2023, primarily due to fair value losses on investor options and interest expenses [5][23]. - Cash and cash equivalents stood at US$131.9 million as of December 31, 2024, with a cash runway expected to extend through the anticipated topline data readouts of the Phase 3 trials COAST and ShORe [2][5]. - Net cash flows used in operating activities were US$72.6 million, compared to US$69.4 million in the prior year [5]. Clinical Development Program - Opthea is conducting two pivotal Phase 3 clinical trials, COAST and ShORe, aimed at evaluating the efficacy of sozinibercept in combination with standard anti-VEGF-A therapies for wet AMD [9][14]. - Topline results from the COAST trial are expected in early Q2 CY2025, while results from the ShORe trial are anticipated in mid-CY2025 [6][9]. - Sozinibercept has received Fast Track Designation from the US FDA, indicating its potential to address significant unmet medical needs in wet AMD [9]. Product Overview - Sozinibercept is a first-in-class VEGF-C/D 'trap' inhibitor designed to improve vision in wet AMD patients, potentially becoming the first therapy in nearly 20 years to demonstrate superior visual outcomes [8][14]. - The drug targets the inhibition of VEGF-C and VEGF-D, which are known to contribute to retinal diseases, thereby preventing blood vessel growth and vascular leakage [8]. Corporate Highlights - Recent corporate developments include the appointment of new executives and the completion of a significant capital raising initiative totaling approximately A$227.3 million (US$150 million) [6][9]. - Opthea joined the S&P/ASX 300 Index in September 2024, reflecting its growing market presence [6].

Core Viewpoint - Opthea Limited has successfully completed its drug product Process Performance Qualification (PPQ) campaign for sozinibercept, which supports a potential biologics license application (BLA) filing in the first half of calendar year 2026 [2][3][4]. Company Overview - Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) [5]. - The lead product candidate, sozinibercept, is a first-in-class VEGF-C/D 'trap' inhibitor, currently in Phase 3 development, aimed at providing superior vision outcomes for wet AMD patients [6]. Manufacturing and Development Progress - The PPQ campaign involved the successful production of three consecutive commercial-scale drug product batches, validating Opthea's manufacturing process for sozinibercept [3]. - The completion of the drug product PPQ campaign is a significant milestone in preparation for the potential BLA filing and commercialization of sozinibercept [4]. Future Outlook - The company is working towards the Phase 3 topline data readout for the COAST trial in early Q2 CY2025 and the ShORe trial in mid-CY2025, which are critical for the future of sozinibercept [4].

Core Insights - BT Group has expanded its partnership with Optiva to implement innovative B2B and B2B2X network communication services, enhancing its capabilities in enterprise services [1][5] - The collaboration focuses on utilizing Optiva's cloud-native Application Server and Charging Engine to modernize BT Group's service offerings and create new revenue opportunities [1][2] Group 1: Partnership and Technology Implementation - The partnership aims to evolve BT Group from legacy technology to a modernized platform that supports increased 5G network coverage and flexible service creation [2][4] - Optiva's new interfaces and technologies are transforming BT Group's traditional network into a next-generation network, essential for both B2B and consumer applications [3][4] Group 2: Strategic Goals and Future Growth - The modernization of B2B applications is crucial for BT Group's service evolution, with a focus on enhancing network convergence capabilities [3][4] - Both companies are committed to a joint vision of expanding B2B and B2B2X services, which will drive BT Group's growth and technological advancements [5][4]

Core Insights - Opthea Limited has completed the final week 52 patient visit in the COAST Phase 3 trial, which evaluates the superiority and safety of sozinibercept combined with aflibercept for treating wet AMD [1][2] - Topline results from the COAST trial are expected in early Q2 CY25, while results from the ShORe trial are anticipated in mid-CY25 [1][2] Company Overview - Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) [3] - The lead product candidate, sozinibercept, is a first-in-class VEGF-C/D 'trap' inhibitor aimed at providing superior vision outcomes for wet AMD patients [4] Clinical Trials - Opthea is conducting two pivotal Phase 3 trials: COAST (combination of OPT-302 with Aflibercept) and ShORe (combination of OPT-302 with Ranibizumab) [2] - The primary endpoint for both trials is the mean change in Best Corrected Visual Acuity (BCVA) from baseline to week 52 [2] - Patients will continue treatment for an additional year post-week 52 to assess extended safety and tolerability [2] Regulatory Status - Sozinibercept has received Fast Track Designation from the US FDA for the treatment of wet AMD, which may facilitate its development and approval process [2]

Core Insights - Optiva Inc. has integrated agentic AI into its BSS platform, enhancing operational efficiency, reducing costs, and improving customer experience for telecom companies [1][3][5] - The technology leverages Google's Gemini models to enable intelligent process automation and hyper-personalized customer interactions [5][6] Industry Impact - By 2028, it is projected that 33% of enterprise software applications will incorporate agentic AI, a significant increase from 1% in 2024, indicating rapid adoption and potential for economic growth [4] - McKinsey identifies customer operations and sales as primary areas for GenAI revenue generation, highlighting the importance of AI agents in future business strategies [4] Benefits of Optiva's AI Solutions - Enhanced Customer Experience: The AI agent Amica automates customer queries, improving resolution times and satisfaction [9] - Increased Operational Efficiency: The AI agent Kairos reduces ticket resolution time and manual efforts, optimizing resource allocation [9] - Hyper-Personalized Engagement: The AI agent Sophos enables CSPs to offer tailored plans, enhancing sales efficiency and customer loyalty [9]